Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

Innerchild Aug. 18 at 8:38 PM

$GDC Damon says: Don’t miss out on 50-60x ticker tonight AH will be wild he says! $SIDU $MTEN $JSPR $MNTS

1 · Reply

Mario19860 Aug. 18 at 2:32 PM

$JSPR Someone is manipulating this stock. I've had money invested in it for two years now, and it's the same old crap again.

0 · Reply

TM555 Aug. 17 at 7:54 PM

$JSPR

1 · Reply

Mario19860 Aug. 17 at 6:59 AM

$JSPR every time good news this stock fail...

0 · Reply

focafoca99 Aug. 14 at 4:27 PM

$JSPR raises $132 million in PIPE financing and reports Q2 2026 results, including the Kira Pharmaceuticals acquisition.

0 · Reply

PGMG Aug. 13 at 5:37 PM

$JSPR well I am loosing a bit less since I posted this. What a crazy stock this is

1 · Reply

ajmrtxl Aug. 13 at 3:20 PM

$JSPR 's latest squeeze play

0 · Reply

NNTrader Aug. 13 at 3:12 PM

$JSPR keep going

0 · Reply

Mario19860 Aug. 12 at 1:06 PM

$JSPR i cant buy jspr stock , but i can sell... What is happening?

3 · Reply

Cache_Money Aug. 12 at 1:59 AM

$JSPR Briquilimab seems to have a dubious future because of the neutropenia and this company seems like amateur hour with the trial issues they’ve had. That said, KP-104 seems like it has actual potential and the licensing deal with Mirador is promising. By the way, keep an eye on Mirador and be ready for their IPO if it happens this year.

0 · Reply

Jasper Therapeutics initiated with an Overweight at Piper Sandler

Aug 14, 2026, 11:00 AM EDT - 4 days ago

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Jasper Therapeutics Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Jasper Therapeutics Earnings release: Q2 2026

2026-07-16T21:45:10.000Z - 4 weeks ago

Jasper Therapeutics trading resumes

2026-07-16T21:25:20.000Z - 4 weeks ago

Jasper Therapeutics completes acquisition of Kira Pharmaceuticals

Jul 16, 2026, 5:15 PM EDT - 4 weeks ago

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

2026-07-16T21:10:11.000Z - 4 weeks ago

Jasper Therapeutics trading halted, news pending

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Jasper Therapeutics Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Jasper Therapeutics Proxy statement: Proxy filing

2026-06-01T12:26:26.000Z - 2 months ago

Jasper Therapeutics initiates review of strategic alternatives

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

2026-05-15T13:18:13.000Z - 3 months ago

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

2026-05-15T09:40:09.000Z - 3 months ago

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

May 14, 2026, 4:05 PM EDT - 3 months ago

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 7:00 AM EDT - 3 months ago

Jasper Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Jasper Therapeutics Earnings release: Q1 2026

2026-04-01T11:59:40.000Z - 5 months ago

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

2026-03-30T20:37:13.000Z - 5 months ago

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

Mar 30, 2026, 4:30 PM EDT - 5 months ago

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Jasper Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Jasper Therapeutics Annual report: Q4 2025

2026-03-23T10:20:58.000Z - 5 months ago

Jasper Therapeutics assumed with a Neutral at UBS

Mar 2, 2026, 3:50 PM EST - 6 months ago

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 6 months ago

Jasper Therapeutics Slides: Corporate presentation

Feb 24, 2026, 4:30 PM EST - 6 months ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

2026-01-13T20:20:15.000Z - 7 months ago

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

Jan 8, 2026, 8:00 AM EST - 7 months ago

Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 7 months ago

Jasper Therapeutics Press release: Study Result

Jan 8, 2026, 8:00 AM EST - 7 months ago

Jasper Therapeutics Slides: Study Result

2026-01-08T12:15:17.000Z - 7 months ago

Jasper Therapeutics reports updated data from briquilimab studies

Jan 8, 2026, 7:00 AM EST - 7 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

2026-01-07T21:35:34.000Z - 7 months ago

Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

Jan 7, 2026, 4:30 PM EST - 7 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

2025-12-04T16:57:00.000Z - 9 months ago

3 Penny Stocks to Watch Now, 12/4/25

Dec 3, 2025, 3:00 PM EST - 9 months ago

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Press release: Study Result

Dec 2, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Slides: Study Result

2025-12-02T12:10:33.000Z - 9 months ago

Jasper Therapeutics reports data from ETESIAN Phase 1b study

Dec 2, 2025, 7:00 AM EST - 9 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 9 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 12, 2025, 3:30 PM EST - 9 months ago

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 4:00 PM EST - 10 months ago

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 7:00 AM EST - 10 months ago

Jasper Therapeutics Slides: Investor Presentation

2025-11-10T13:05:12.000Z - 10 months ago

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

Nov 10, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 10 months ago

Jasper Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Sep 22, 2025, 1:05 PM EDT - 11 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

2025-09-22T10:55:06.000Z - 11 months ago

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

2025-09-19T10:00:28.000Z - 11 months ago

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

Sep 19, 2025, 12:07 AM EDT - 11 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

2025-09-18T20:15:24.000Z - 11 months ago

Jasper Therapeutics announces common stock offering, no amount given

Sep 18, 2025, 4:08 PM EDT - 11 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 3, 2025, 1:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 6:00 PM EDT - 1 year ago

Jasper Therapeutics Slides: Corporate Presentation

2025-08-15T11:35:55.000Z - 1 year ago

Jasper Therapeutics price target lowered to $25 from $29 at UBS

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q2 2025

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Update

Jul 7, 2025, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Investor Presentation

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Status Update

Jun 14, 2025, 10:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 21, 2025, 11:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q1 2025

Mar 27, 2025, 12:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Registration statement: Registration Filing

Mar 3, 2025, 1:20 PM EST - 1 year ago

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Press release: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Slides: Study Update

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 3, 2024, 3:25 PM EST - 1 year ago

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 9:45 AM EST - 1 year ago

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Quarterly report: Q3 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 8:00 AM EDT - 2 years ago

Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 2 years ago

Jasper Therapeutics Press release: Study Result

Oct 14, 2024, 8:00 AM EDT - 2 years ago

Jasper Therapeutics Slides: Study Result

Oct 14, 2024, 7:00 AM EDT - 2 years ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Innerchild Aug. 18 at 8:38 PM

$GDC Damon says: Don’t miss out on 50-60x ticker tonight AH will be wild he says! $SIDU $MTEN $JSPR $MNTS

1 · Reply

Mario19860 Aug. 18 at 2:32 PM

$JSPR Someone is manipulating this stock. I've had money invested in it for two years now, and it's the same old crap again.

0 · Reply

TM555 Aug. 17 at 7:54 PM

$JSPR

1 · Reply

Mario19860 Aug. 17 at 6:59 AM

$JSPR every time good news this stock fail...

0 · Reply

focafoca99 Aug. 14 at 4:27 PM

$JSPR raises $132 million in PIPE financing and reports Q2 2026 results, including the Kira Pharmaceuticals acquisition.

0 · Reply

PGMG Aug. 13 at 5:37 PM

$JSPR well I am loosing a bit less since I posted this. What a crazy stock this is

1 · Reply

ajmrtxl Aug. 13 at 3:20 PM

$JSPR 's latest squeeze play

0 · Reply

NNTrader Aug. 13 at 3:12 PM

$JSPR keep going

0 · Reply

Mario19860 Aug. 12 at 1:06 PM

$JSPR i cant buy jspr stock , but i can sell... What is happening?

3 · Reply

Cache_Money Aug. 12 at 1:59 AM

0 · Reply

LORAXX Aug. 11 at 5:54 PM

$JSPR Nothing for sale. Shorty needs to pay the piper to get out out of this one and that's one hell of a gap up.

0 · Reply

Chrissytina Aug. 11 at 4:40 PM

$JSPR Squeeze baby!!! LFG

0 · Reply

LORAXX Aug. 11 at 4:14 PM

$JSPR

0 · Reply

ajmrtxl Aug. 11 at 3:53 PM

$JSPR 's latest data on SqueezeFinder

0 · Reply

NNTrader Aug. 11 at 3:52 PM

$JSPR bullish

0 · Reply

ajmrtxl Aug. 10 at 4:19 PM

$JSPR 's latest data on SqueezeFinder

0 · Reply

topstockalerts Aug. 10 at 4:12 PM

$JSPR setting up nicely here

0 · Reply

buttercup1007 Aug. 10 at 4:09 PM

$JSPR looks like cup and handle. Pt above 1

0 · Reply

Bullish_Visions Aug. 10 at 3:52 PM

AIFA has the look, the chart+the DD to make a big rally soon. Make sure to put AIFA on ur watch! Always best to position ur self early on these parabolic setups. $JZ $JZXN $JSPR $NEXR ..11 9

0 · Reply

NNTrader Aug. 7 at 4:23 PM

$JSPR

0 · Reply

focafoca99 Jul. 31 at 10:17 AM

$JSPR confirms CVR holders will get a $30 M milestone if FDA grants a priority review voucher for briquilimab.

1 · Reply

Biobio4 Jul. 28 at 1:52 PM

$JSPR what now??

1 · Reply

Market Cap	23.58M
Revenue (ttm)	0.00
Net Income (ttm)	-75.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,997,400
Avg Vol	1,661,654
Day's Range	N/A - N/A
Shares Out	28.00M
Stochastic %K	35%
Beta	3.02
Analysts	Sell
Price Target	$6.50